Moderna won’t advance US-backed Zika vaccine without more outside funding

Moderna does not plan to advance a midstage Zika vaccine without additional outside cash, despite receiving US funding thus far, according to a regulatory disclosure.

The news, tucked into Moderna’s annual report released Friday, throws cold water on the most mature vaccine in Moderna’s public health pipeline. The company is also working on vaccines for mpox and Niphah under the public health umbrella, both of which are in phase 1 studies.